

Special Issue

Genetics in Hematological Malignancies

Message from the Guest Editor

Hematological malignancies, including leukemias, lymphomas, and myelomas, are characterized by complex genetic alterations that drive their pathogenesis. This Special Issue aims to explore the role of genetics in understanding these diseases, focusing on recent advancements in genomic technologies and their application in clinical practice. Topics may include the discovery of novel genetic mutations, the impact of epigenetics on disease progression, and the importance of genetic profiling for personalized treatment strategies. Additionally, the Special Issue will highlight the significance of next-generation sequencing and bioinformatics in identifying biomarkers for diagnosis and prognosis. By fostering a deeper understanding of the genetic landscape of hematological malignancies, it seeks to contribute to the development of innovative therapeutic approaches and improve patient outcomes.

Guest Editor

Dr. Monika Lejman

Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, Geばali 6, 20-093 Lublin, Poland

Deadline for manuscript submissions

closed (10 May 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/226315

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)